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Introduction
Nasal polyposis (NP) is a multifactorial dis-
ease involving nasal mucosa, and occuring in
about 1-4% of the population [1]. Increased plas-
ma concentrations of different Th1 (TNF-alpha,
IL-1, IL-6), Th2 (IL-5, IL-4) cytokines, and other
inflammation-related mediators have been found
in NP [2]. Eosinophils are the most abundant cell
type, indeed high IgE concentrations have been
found in NP [3]. Several pro-infiammatory cy-
tokines, such as IL-4 and IL-5 have been implicat-
ed in inducing eosinophils production, eliciting tis-
sue damage and finally promoting airway remod-
elling in NP [4]. It has been recently proposed that
nasal polyposis can propagate from upper to lower
airways [5]; however, mechanisms binding upper
and lower airway inflammation in NP remain
poorly understood. Two theories are mainly ac-
cepted and include an activation of nasal reflexes,
or pulmonary aspiration of nasal contents [6].
Several methods are available to collect and
analyse samples from upper and lower airways,
such as bronchial and nasal biopsy, bronchoalveo-
lar lavage (BAL), nasal lavage, nasal brushing, and
nasal secrete collection. They are invasive or semi-
invasive assays, need specific competence, and are
non-repeatable in clinical practice. These impedi-
ments enhance the importance of assessing an easy,
alternative, and non-invasive method to better ex-
plore the upper and lower respiratory system and to
acquire additional features in nasal polyposis.
The exhaled breath condensate is a new, non-
invasive method, is able to detect inflammatory
and metabolic markers of the airways and can be
performed with good reproducibility [7]. Recently,
Griese and colleagues modified breath condensate
collections by applying a nasal prong to the device,
usually used for oxygen delivery [8]. This new
adapted method is more comfortable and efficient
to assemble the exhaled air condensate from the
upper airways (including nasal cavities) [9]. Sev-
eral inflammatory markers such as IL-1ß [10], IL-
8 [10], IL-6 [11], IL-10 [12], TNF-α [10] and
LTB4 [13] have been observed in orally exhaled
breath condensate of individuals affected by dif-
ferent respiratory diseases. The present study was
designed to investigate IL-6 and IL-4 concentra-
tions in nasally and orally exhaled breath conden-
sate of healthy subjects and of patients with early
(grade 1) and advanced (grade 2-3) NP, to verify
whether these markers are increased in patients
with NP and change after polypectomy.
Material and Methods
Study design
We enrolled into the study ten patients with
polyposis in early status (41±9 years, FEV1
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Background and Aim. Nasal polyposis (NP) occurs in
about 1-4% of the worldwide population. Increased plas-
ma concentrations of different pro-inflammatory cy-
tokines have been observed in NP, and might be related to
the pathogenesis of this syndrome.The present study was
designed to investigate IL-6 and IL-4 concentrations in
nasal and oral exhaled breath condensate of patients with
early and advanced NP, and following polypectomy.
Methods. Ten individuals with polyposis in early sta-
tus, twenty-three patients affected by advanced status of
NP and ten healthy controls were enrolled into the study.
Exhaled breath condensate was collected by all individu-
als, according to a previous standardised method. An im-
munoassay kit was used to measure IL-6 and IL-4 levels.
Results. Concentrations of oral and nasal exhaled IL-
6 and IL-4 were significantly higher in patients with early
nasal polyposis and advanced nasal polyposis, compared
to healthy controls. A statistically significant decrease of
nasally but not of orally exhaled IL-6 (p<0.001) and IL-4
(p<0.05) was observed after polypectomy.
Conclusions. We consider oral and nasal exhaled con-
densate of IL-6 and IL-4 as valid inflammatory and ox-
idative stress marker in patients with nasal polyposis.
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95.1±1.2, FVC 93.6±2.2%, BMI 24±0.4 kg/m2),
twenty-three patients affected by advanced status
of NP (46±3 years, FEV1 105.5±2.1, FVC
98.4±2.3%, BMI 25±0.6 kg/m2), and ten healthy
controls (43±9 years, FEV1 120.1±11.2, FVC
119±3.4%, BMI 24±0.5 kg/m2). Both, patients and
healthy controls were Caucasian and selected from
the Department of Otorhinolaryngology, Universi-
ty of Bari. Informed written consent was obtained
by all subjects. The study was approved by the In-
stitutional Ethics Committee. The diagnosis of NP
was made endoscopically and classified according
to the International Conference on Sinus Disease
[14]. All patients selected into the study were non-
smokers, did not have nasal, bronchial, or lower
respiratory tract infection, as well as chronic cough
before the enrollment and/or during the study peri-
od. We excluded from the study patients affected
by bronchial asthma [15] and individuals with
bronchial hyperresponsiveness, according to
methacholine provocative test [16]. Patients affect-
ed by aspirin-induced-asthma were also ruled out
from the study: the diagnosis was made on basis of
positive inhalation (bronchial) provocation test
[17]. We finally excluded patients affected by
sleep disturbances (patients enrolled showed an
AHI score of <10).
All patients were affected by bilateral NP, had
negative skin prick test, and were free from thera-
py for at least 15 days before the admission to the
study. Only nasal lavage with isotonic saline solu-
tion was allowed. All subjects performed pul-
monary function test, methacholine challenge,
bronchial provocation test with aspirin, nasal en-
doscopy, and nasal cytology. All subjects under-
went oral and nasal breath condensate collection
one day after previous examinations. Ten patients
with NP were investigated 30 days after polypec-
tomy with nasal endoscopy, nasal cytology, at
baseline and after decongestion rhinomanometry.
They underwent oral and nasal breath condensate
collection one day after previous examinations.
Skin test assessment
Skin prick tests were performed as previously
described for common aeroallergens (Lofarma,
Italy) [18].
Lung function
Pulmonary function tests were performed
within 1 day of the measurement of the breath con-
densate being measured. The forced expiratory
volume in one second (FEV1) and the forced vital
capacity (FVC) were measured using a spirometer
(Sensormedics, USA). Of three manoeuvers the
best value was expressed as a percentage of the
predicted normal value.
Nasal endoscopy
Nasal endoscopy was performed in local anes-
thesia, using a flexible fiberscope (Vision Science
ENT-2000, Massachusetts, USA). We used the
modified rhino-fiberscopic score of an Internation-
al Conference on Nasal Polyposis [14]: 0 = absence
of polyp, 1 = polyp in medium meato, 2 = polyp
that comes out from meato, 3 = massive polyposis.
Nasal cytology
Cytological sampling was performed by scrap-
ing with a Rhino-Probe (Apotex Scientific, Inc.,
Arlington, TX) in the middle part of the lower
turbinate, which is located in an area characterised
by a significant number of cells, in particular cili-
ated cells. Fixed with methyl alcohol for 4 min-
utes, the slides were coloured with the May Grun-
wald.Giemsa (MGG) staining method.
The microscopic observation with a 400X en-
largement allowed us to check cell distribution,
1000X magnification, in immersion, allowed to
distinguish different inflammatory cells. The cellu-
lar evaluation was performed through a semi-quan-
titative study taking in exam 10 microscopic areas.
Basal and after decongestion rhinomanometry
All individuals underwent a basal and after de-
congestion rhino-manometry (Rhinomanometer
Memphis, amplifon, Italy). The measure unit for
the rino-manometry was PA/cc/sec being the pres-
sion expressed in Pascal and the flow in cc/sec.
The pression flow was established by an Institu-
tional Committee for standardization of rino-
manometry at 150 Pascal.
Exhaled breath condensate
The oral exhaled breath condensate was col-
lected using a condenser which allowed the non-in-
vasive collection of the non-gaseous components
from the expired air (EcoScreen, Jaeger, Wurzburg,
Germany). Individuals breathed through a mouth-
piece and a two-way non-rebreathing valve, which
also served as a saliva trap. They were asked to
breathe at a normal frequency and tidal volume,
wearing a nose clip for a period of 10 minutes. If
subjects felt saliva in their mouth they were in-
structed to swallow it. Nasal exhaled breath con-
densate was collected applying a facial mask to the
EcoScreen, asking subjects to breathe through their
nose, with their mouths closed. Condensate, at least
1 ml, was collected on ice at –20o C, transferred to
Eppendorf tubes and stored at -80o C immediately.
Measurement of IL-6 and IL-4
A specific enzyme immunoassay (EIA) Kit
(Cayman Chemical, Ann Arbor, MI) was used to
measure IL-6 and IL-4 concentrations in breath
condensate. The assays were validated directly by
gas chromatography/mass spectrophotometry. The
intraassay and interassay variability were ≤10%.
The detection limits of the assays were 20 pg/ml
and 1.5 pg/ml respectively. The comparison be-
tween oral and nasal concentration of exhaled IL-
4 and IL-6 were performed according to an as-
sessed method [8].
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Analysis
Data is expressed as means ± SD. A Mann-
Whitney test was used to compare groups. Corre-
lations between variables were performed using
Spearman’s rank correlation test. Significance was
defined as a p value of <0.05.
Results
IL-6
The three subject groups were similar with re-
spect to their lung function (p<0.01). Concentra-
tions of orally and nasally exhaled IL-6 were sig-
nificantly higher in patients with early nasal poly-
posis (grade 1) (4.9±0.4 and 4.6±0.4 pg/ml) and
advanced nasal polyposis (grade 2-3) (5.2±0.2 and
6.6±0.3) compared to healthy controls (2.8±0.1
and 2.7±0.1) (fig. 1). Significantly more elevated
concentrations of IL-6 were observed in nasally
than in orally exhaled breath condensate of pa-
tients with nasal polyposis (p<0.005), while no dif-
ferences were found in healthy subjects.
A statistically significant decrease of nasally
exhaled IL-6 (6.5±1.4 vs 4.4±0.2 pg/ml, p<0.001),
but not of orally exhaled IL-6 (4.9±1.1 vs 4.3±0.2
pg/ml) was observed after polypectomy (fig. 2).
A positive correlation between nasally exhaled
IL-6 and number of neutrophils in nasal scraping
was also observed (r=0.5, p<0.01).
Reproducibility of exhaled IL-6 measurements
was assessed in 10 non-smoking normal (35±7
years) subjects. In most of measurements, differ-
ences between IL-6 values ranged within ± 2SD
(mean difference -0.03 ± 0.24 pg/ml). The co-effi-
ciency of variation for measured IL-6 was 5.9%.
IL-4
Concentrations of orally and nasally exhaled
IL-4 were significantly higher in patients with ear-
ly nasal polyposis (39.9±0.8 and 55.8±1.9 pg/ml)
and in patients with higher grades of polyposis
(65.9±1.7 and 80.9±2.2), compared to healthy con-
trols (35.8±1.1 and 37.7±1.1) (fig. 3). Significant-
ly more elevated concentrations of IL-4 were ob-
served in nasally exhaled breath condensate than
in orally, either in patients with advanced nasal
polyposis (p<0.0001) and in
those with early nasal polyposis
(p<0.05), while no differences
were found in healthy subjects.
The decrease of nasally ex-
haled IL-4 (84.0±8.9 vs 63.8±1.7
pg/ml, p<0.05) (fig. 4) but not
orally exhaled IL-4 (64.6±8.5 vs
56.1±3.1 pg/ml) after polypecto-
my was statistically significant.
A positive correlation was
observed between nasally ex-
haled IL-4 and the number of
eosinophils in nasal scraping
(r=0.6, p<0.005).
Reproducibility of exhaled
IL-4 measurements was assessed
in 10 non-smoking normal (35±7
yr) subjects. In most of measure-
ments, the differences between
the two IL-4 values ranged with-
in ± 2SD (mean difference -0.03
± 1.05 pg/ml). The co-efficiency
of variation for IL-4 measured
was 4.2%.
Discussion
In the present study, we ob-
served significantly higher con-
centrations of orally and nasally
exhaled condensate of IL-6 and
IL-4 in patients with early and ad-
vanced polyposis compared to
healthy controls. However, these
concentrations were significantly
more elevated in nasally exhaled
breath condensate than in orally
breath condensate of patients
with nasal polyposis. Further-
Fig. 2. - IL-6 concentrations in orally and nasally exhaled breath condensate of patients nasal
polyposis (NP) before and after polypectomy.
Fig. 1. - IL-6  concentrations in orally and nasally exhaled breath condensate of patients with
early nasal polyposis (NP), advanced nasal polyposis (NP) and of healthy controls (H).
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more, we found a significant decrease of nasally
exhaled IL-6 and IL-4 after polypectomy, while we
did not observe a significant difference in orally
exhaled IL-6 and IL-4 after polypectomy. We also
demonstrated a positive correlation between nasal-
ly exhaled IL-6 with number of neutrophils in
nasal scraping and nasally exhaled IL-4 with num-
ber of eosinophils in nasal scraping.
Nasal polyposis is characterised by infiltration
of inflammatory cells, including mast cells,
eosinophils, lymphocytes and neutrophils [19]. Al-
though the exact mechanism elucidating the patho-
genesis of NP is not clearly understood, a wide
spectrum of cytokines seems to play an important
role in developing NP [20]. The pro-inflammatory
cytokines IL-4, which modulates the function of
eosinophils and is widely produced by T cells and
mast cells, and IL-6, which actively participate to
the inflammatory response, and is mainly released
by neutrophils and macrophages [21], permanent-
ly contribute to perpetuate the mucosal inflamma-
tion of patients with NP. IL-4 has been previously
utilised to investigate eosinophilic inflammation in
nasal lavage of patients with NP [19], is also able
to induce cells apoptosis and to promote airway
eosinophilia [22]. IL-6 has been
widely studied in inflammatory
diseases and has been previously
found enhanced in nasal polyps
epithelial cell-conditioned medi-
um and in polyps tissue of sub-
jects with NP [23]. IL-6 is a mul-
tifunctional cytokine: in addition-
al to its modulating role in in-
flammatory diseases, IL-6 has
been suggested to promote colla-
gen deposition and subsequent
airway remodelling in NP [24].
To our knowledge, this is the
first study in which the exhaled
breath condensate assay was used
to establish airway inflammation
of upper respiratory airways in
nasal polyposis. Biochemical
analysis of breath condensate is
an emerging, non invasive assay
to assess airway inflammation on
respiratory airways. It is the ulti-
mate way of collecting exhaled
breath condensate results in a
manner which is easier, safer,
does not require active co-opera-
tion, and is completely non-inva-
sive [25]. This method has been
used largely to study several in-
flammatory diseases, such as
chronic obstructive pulmonary
disease (COPD), allergic rhinitis,
and asthma [26]. We assessed a
modified nasally collection of
breath condensate applying a
nasal mask to the patients, who
were asked to keep their mouth
closed during the test. In addition,
exhaled air, collected in this way
bypassing the mouth, did not present any salivary
contamination. In this study, we concomitantly
used the oral and the nasal exhaled breath conden-
sate collection to explore the entire upper airway
system. The hypothesis that upper airways inflam-
mation can propagate to lower airways in NP has
been recently predicted[5]. Lamblin and col-
leagues described bronchial changes in subjects
with NP [6], and subsequent studies confirmed the
presence of lower inflammation in NP [27]. Since
we found elevated concentrations of IL-4 and IL-6
in oral and in nasal exhaled breath condensate of
patients with NP, the upper and lower airways ap-
pear, in these condition, to be strongly involved.
We further showed that nasally and orally IL-4 and
IL-6 levels significantly correlated with
eosinophils and neutrophils increase in nasal
scrubbing, respectively. Our data confirms the role
of these cytokines as markers of eosinophilic and
neutrophilic inflammation. In consideration of the
strong correlation largely known between
eosinophils and exhaled NO and of the usefulness
recently proposed of eNO in the clinical and ther-
apeutic follow up and in the control of patients
with eosinophilic inflammation the use of eNO in
Fig. 3. - IL-4  concentrations in orally and nasally exhaled breath condensate of patients with
early nasal polyposis (NP), advanced nasal polyposis (NP) and of healthy controls (H).
Fig. 4. - IL-4  concentrations in orally and nasally exhaled breath condensate of patients nasal
polyposis (NP) before and after polypectomy.
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association to the exhaled markers analysed could
be proposed also in the management of patients
with nasal polyposis [28]. Interestingly, the de-
crease of nasal, but not of oral exhaled condensate
concentrations of IL-6 and IL-4 after polypectomy
might correlate with the decline of upper but not
lower airway inflammation in these patients. Con-
troversial results exist in the treatment of sinonasal
polyps and its involvement in lower airways. In
fact, Batra et al demonstrated that the treatment of
endoscopic sinus surgery may significantly reduce
lower airway inflammation [29], while other au-
thors failed to show this specific relationship [30].
Probably, the effects of polypectomy in reducing
lower airway inflammation may require a longer
time.
In conclusion, we believe that oral and nasal
exhaled condensate of IL-6 and IL-4 could be ap-
plicable as a valid marker of inflammation and ox-
idative stress in upper and lower airways of pa-
tients with nasal polyposis. In addition, being mea-
surable in a simple, non-invasive, economical, and
repeatable manner, it might be utilised in clinical
practice for identification and monitoring upper
and lower airways inflammation in NP, and for the
evaluation of post-surgical effects of NP.
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